Investment
Features
FeesSafety
Academy
More
Pluang+

Ethereum needs 64% gain to reclaim $4,000 amid ETF outflows and network upgrades.

Market News
19 Oct 2026
Coinpaper
View Source
Neutral
Ethereum needs 64% gain to reclaim $4,000 amid ETF outflows and network upgrades.

Ethereum is currently trading around $2,445, about 39% below the $4,000 mark, requiring a 64% gain to recover. The cryptocurrency has faced institutional selling and weak market momentum throughout 2026, with nearly $955 million withdrawn from U.S. spot ETH ETFs in early October. Despite these challenges, upcoming network upgrades like the Glamsterdam testnet activation and staking opportunities could support a recovery. A sustained rebound depends on stronger market participation and stabilized fund flows, with a potential return above $4,000 projected for 2027.

Ethereum price prediction is the subject, with market context from Pluang's cryptocurrency breadth data. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 19, 2026 18:21 WIB: out of 50 major cryptocurrencies, 23 rose and 25 fell today. Notable movers include EOS up 8.13% at Rp12.649 with a typical hold time of 87 days, SAND down 5.96% at Rp1.040 with 35% sell and 65% buy order activity, and CRV up 3.99% at Rp6.334 with 43% sell and 57% buy order activity and a typical hold time of 62 days.

More News

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...

Others
Neutral
1 hour ago
EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...

Company Fundamentals
Neutral
1 hour ago
Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

Market News
Bullish
1 hour ago
Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...

Company Fundamentals
Bullish
1 hour ago
JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App